FDA Requires Safety Labeling Changes For GLP-1 RAs Due To Potential Increased Risk Of Rare But Serious Eye Condition
The FDA issued a Drug Safety Communication on November 9, 2026 informing patients and health care providers of a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) associated with use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. NAION is a rar[...]